Infantile Polycystic Kidney Disease Medical Services in China

Infantile Polycystic Kidney Disease (IPKD), now more accurately termed Autosomal Recessive Polycystic Kidney Disease (ARPKD), is a rare, life-threatening genetic disorder characterized by bilateral renal cystic dilation of the collecting ducts and congenital hepatic fibrosis. It results from biallelic pathogenic variants in the PKHD1 gene on chromosome 6p12.2, which encodes fibrocystin/polyductin — a ciliary protein critical for normal tubular morphogenesis and bile duct development. Dysfunctional fibrocystin disrupts planar cell polarity, cilia-mediated signaling (e.g., cAMP, Wnt, and Hedgehog pathways), and epithelial integrity, leading to progressive cyst formation in kidneys and periportal fibrosis in the liver. Unlike autosomal dominant PKD, ARPKD manifests prenatally or in early infancy, with severity varying widely: severe cases present with oligohydramnios, Potter sequence, pulmonary hypoplasia, and neonatal respiratory failure; milder forms may present later with hypertension, renal insufficiency, or portal hypertension due to liver involvement. The estimated incidence is 1 in 20,000 to 1 in 40,000 live births, with carrier frequency ~1:70 in the general population. Consanguinity significantly increases risk, and no sex predilection exists. Diagnosis relies on prenatal ultrasound (enlarged, echogenic kidneys ± oligohydramnios), postnatal imaging (renal ultrasound showing symmetric enlargement and increased echogenicity; MRI for hepatic fibrosis assessment), and confirmatory genetic testing. Complications include chronic kidney disease (CKD) progressing to end-stage renal disease (ESRD) in ~30–50% by age 10–15 years, systemic hypertension (often refractory), urinary tract infections, growth failure, and complications of portal hypertension (variceal bleeding, hypersplenism). Quality of life is profoundly impacted: infants face intensive neonatal care and recurrent hospitalizations; children experience developmental delays, school absenteeism, dietary restrictions, and psychosocial stress related to chronic illness, dialysis dependence, or transplant candidacy. Families endure emotional burden, financial strain, and caregiving demands. Long-term management requires multidisciplinary coordination among pediatric nephrology, hepatology, nutrition, genetics, and palliative care. While no disease-modifying therapy yet exists, supportive care—aggressive blood pressure control, electrolyte management, nutritional support, infection prophylaxis, and timely renal replacement therapy—is essential to optimize survival and neurodevelopmental outcomes. Emerging research focuses on CFTR modulation, cAMP inhibition, and antifibrotic agents, but clinical translation remains investigational.

Infantile Polycystic Kidney Disease (IPKD), now more accurately classified as Autosomal Recessive Polycystic Kidney Disease (ARPKD), is a rare, genetically determined disorder characterized by bilateral renal cystic dilation of the collecting ducts and congenital hepatic fibrosis. It is distinct from the more common Autosomal Dominant Polycystic Kidney Disease (ADPKD) in inheritance pattern, age of onset, histopathology, and extrarenal manifestations. The primary cause of ARPKD is biallelic pathogenic variants in the PKHD1 gene (Polycystic Kidney and Hepatic Disease 1), located on chromosome 6p12.2. PKHD1 encodes fibrocystin/polyductin, a large transmembrane protein predominantly expressed in renal collecting duct epithelia, bile duct epithelia, and pancreatic ducts. Fibrocystin functions as a receptor or co-receptor in ciliary signaling pathways—particularly those involving planar cell polarity, calcium homeostasis, and cAMP regulation—and its loss disrupts tubular morphogenesis, leading to abnormal ductal plate remodeling, cyst formation, and progressive interstitial fibrosis. Over 90% of clinically diagnosed ARPKD cases harbor two disease-causing PKHD1 variants; most are private missense, nonsense, splice-site, or small insertion/deletion mutations, with compound heterozygosity being the predominant genotype. Rarely, atypical or milder phenotypes may arise from hypomorphic alleles or digenic interactions involving other ciliopathy-associated genes (e.g., DZIP1L), though these remain investigational.

Triggers for clinical deterioration are not causative per se but exacerbate underlying pathophysiology. Perinatal respiratory insufficiency—often due to pulmonary hypoplasia secondary to oligohydramnios—is the leading cause of early mortality; this results from severe fetal renal dysfunction impairing amniotic fluid production. Postnatally, triggers include systemic hypertension (driven by renin-mediated activation of the RAAS due to renal ischemia), urinary tract obstruction from cystic enlargement or infection, electrolyte imbalances (e.g., hyponatremia from impaired concentrating ability), and acute kidney injury precipitated by dehydration, nephrotoxic agents (e.g., NSAIDs, aminoglycosides), or sepsis. Hepatic complications—including portal hypertension, variceal bleeding, and cholangitis—may be triggered by ascending bacterial infection in dilated intrahepatic bile ducts or progressive periportal fibrosis.

Key risk factors include consanguinity (increasing the likelihood of homozygous PKHD1 variants), a family history of ARPKD or unexplained neonatal renal failure/hepatic fibrosis, and prenatal ultrasound findings such as enlarged echogenic kidneys, absent or reduced amniotic fluid (oligohydramnios), and Potter sequence features. Ethnicity plays a modest role: ARPKD incidence is estimated at 1:20,000–1:40,000 live births globally, with slightly higher prevalence reported in populations with elevated consanguinity rates (e.g., Middle Eastern, North African, and certain South Asian communities). Male sex is associated with marginally increased perinatal mortality, possibly due to hormonal influences on lung maturation or renal hemodynamics.

Genetic factors are central: ARPKD follows strict autosomal recessive inheritance. Each offspring of carrier parents has a 25% risk of disease, 50% chance of being an asymptomatic carrier, and 25% chance of being unaffected and non-carrier. Genetic counseling and prenatal testing (via chorionic villus sampling or amniocentesis with PKHD1 sequencing) are recommended for at-risk pregnancies. Importantly, PKHD1 exhibits extensive allelic heterogeneity and variable expressivity—even among siblings with identical genotypes—suggesting roles for genetic modifiers (e.g., HNF1B, GANAB) and epigenetic regulation.

Environmental factors do not initiate ARPKD but modulate disease severity and progression. Maternal factors such as chronic hypertension or preeclampsia may worsen placental perfusion and fetal renal blood flow, potentially aggravating oligohydramnios. Postnatal environmental exposures—including recurrent urinary tract infections (especially with uropathogenic E. coli), poor nutritional status limiting growth and immune competence, and exposure to environmental toxins that induce oxidative stress (e.g., heavy metals, air pollutants)—may accelerate renal fibrosis and hepatic inflammation. Additionally, delayed diagnosis or suboptimal management of hypertension, metabolic acidosis, or growth failure contributes to long-term morbidity. While no direct environmental teratogens are implicated in ARPKD pathogenesis, supportive care must address modifiable environmental determinants of outcomes, particularly in resource-limited settings where access to neonatal intensive care, dialysis, or liver-kidney transplantation is constrained.

Infantile Polycystic Kidney Disease (IPKD), now more accurately classified as Autosomal Recessive Polycystic Kidney Disease (ARPKD), is a rare, genetically inherited disorder caused by mutations in the PKHD1 gene on chromosome 6p12.2. It predominantly manifests in utero, neonatally, or during early infancy and is characterized by bilateral, symmetric renal cystic dilation of collecting ducts and congenital hepatic fibrosis. Unlike autosomal dominant PKD, ARPKD exhibits early-onset, severe renal and hepatic involvement with significant morbidity and mortality in the perinatal period.

Early symptoms are often detectable prenatally via ultrasound: enlarged, echogenic kidneys with loss of corticomedullary differentiation, oligohydramnios (due to impaired fetal urine production), and absent or hypoplastic fetal bladder. In severe cases, Potter sequence may develop—comprising pulmonary hypoplasia, characteristic facial features (flattened nose, recessed chin, low-set ears), limb deformities, and intrauterine growth restriction. Postnatally, the earliest clinical signs include respiratory distress (secondary to pulmonary hypoplasia and abdominal distension from massively enlarged kidneys compressing the diaphragm), hypertension (often severe and refractory due to activation of the renin-angiotensin-aldosterone system), and palpable flank masses. Neonates may present with failure to thrive, poor feeding, and metabolic acidosis secondary to reduced glomerular filtration rate (GFR) and tubular dysfunction.

Typical symptoms in surviving infants (beyond the first week of life) include progressive chronic kidney disease (CKD) with manifestations such as polyuria, polydipsia, and nocturia—though these may be subtle in nonverbal infants and inferred from increased wet diapers, dehydration, or recurrent episodes of hypernatremia. Hypertension remains nearly universal and frequently requires multi-drug antihypertensive regimens. Growth retardation is common and multifactorial—attributable to CKD-related anorexia, metabolic acidosis, electrolyte imbalances, and chronic inflammation. Renal enlargement persists and may cause abdominal distension, discomfort, or early satiety. Hepatic involvement becomes increasingly apparent beyond infancy: portal hypertension develops due to progressive periportal fibrosis and biliary dysgenesis, leading to splenomegaly, esophageal varices, and coagulopathy. Cholestasis may manifest as prolonged jaundice, acholic stools, or elevated serum gamma-glutamyl transferase (GGT) and alkaline phosphatase.

Accompanying symptoms reflect multisystem involvement. Neurological sequelae may arise secondarily—e.g., hypertensive encephalopathy presenting with irritability, lethargy, or seizures. Cardiac complications include left ventricular hypertrophy (secondary to chronic hypertension) and, rarely, intracranial aneurysms (though less prevalent than in ADPKD). Gastrointestinal manifestations include recurrent epistaxis or gastrointestinal bleeding (from thrombocytopenia and coagulopathy), malabsorption (due to cholestasis), and protein-losing enteropathy. Endocrine abnormalities include growth hormone resistance, delayed puberty, and vitamin D deficiency with associated rickets or osteodystrophy. Urinary tract infections (UTIs) occur with increased frequency due to urinary stasis and structural abnormalities; recurrent pyelonephritis may accelerate renal functional decline.

Complications are frequent and life-threatening. The most critical neonatal complication is respiratory failure requiring mechanical ventilation—primarily attributable to pulmonary hypoplasia rather than direct renal pathology. Progressive CKD inevitably leads to end-stage kidney disease (ESKD), with approximately 30–50% of affected children requiring renal replacement therapy (dialysis or transplantation) by age 10 years. Hepatic complications include variceal hemorrhage (the leading cause of mortality beyond infancy), hypersplenism with pancytopenia, and ascending cholangitis. Cardiovascular complications encompass heart failure, stroke (from hypertension or embolism), and sudden cardiac death. Additional complications include nephrogenic systemic fibrosis (rare, associated with gadolinium exposure), anemia (due to erythropoietin deficiency and chronic inflammation), and increased susceptibility to sepsis.

Diagnosis relies on a combination of clinical, imaging, genetic, and histopathological assessments. Prenatal ultrasound remains the primary screening tool, with sensitivity exceeding 90% for severe cases when performed after 18 weeks’ gestation. Postnatal renal ultrasound demonstrates bilaterally enlarged, echogenic kidneys without discrete macrocysts (distinguishing ARPKD from multicystic dysplastic kidney or ADPKD); Doppler may reveal abnormal intrarenal arterial resistive indices. Abdominal MRI provides superior delineation of hepatic fibrosis and biliary anatomy. Laboratory evaluation typically reveals elevated serum creatinine, blood urea nitrogen (BUN), and phosphate; metabolic acidosis; anemia; and hyperparathyroidism. Liver function tests show elevated GGT, alkaline phosphatase, and conjugated bilirubin; coagulation studies may demonstrate prolonged PT/INR. Genetic testing for PKHD1 variants confirms diagnosis, especially in atypical or milder phenotypes; however, variant interpretation remains challenging due to the gene’s large size (>67 exons) and high allelic heterogeneity. Renal biopsy is rarely indicated but may show fusiform dilatation of collecting ducts with interstitial fibrosis and preserved glomeruli; liver biopsy reveals characteristic bile duct proliferation and periportal fibrosis.

Differential diagnosis is essential to avoid misclassification. Multicystic dysplastic kidney (MCDK) presents with unilateral, non-communicating, randomly arranged cysts and absence of normal renal tissue—typically sporadic and non-hereditary. Autosomal dominant PKD (ADPKD) usually manifests in adulthood, though early-onset forms exist; imaging shows asymmetric, variably sized cysts involving both cortex and medulla, often with normal or near-normal kidney size initially. Nephronophthisis presents with corticomedullary cysts, tubulointerstitial fibrosis, and progressive CKD but lacks hepatic fibrosis and is associated with extrarenal features like retinitis pigmentosa (Senior-Løken syndrome) or situs inversus (Meckel-Gruber syndrome). Congenital nephrotic syndrome (e.g., NPHS1 mutations) causes massive proteinuria and hypoalbuminemia within the first 3 months but lacks renal enlargement or cysts. Other considerations include renal vein thrombosis (acute onset, Doppler evidence of flow obstruction), prune-belly syndrome (triad of abdominal muscle deficiency, cryptorchidism, and urinary tract dilation), and syndromic disorders such as Meckel-Gruber or Joubert syndrome—distinguished by neuroimaging findings and genetic testing. Accurate differentiation guides prognosis, surveillance strategies (e.g., variceal screening in ARPKD vs. intracranial aneurysm screening in ADPKD), and genetic counseling.

Infantile Polycystic Kidney Disease (IPKD), now more accurately classified under the broader entity of Autosomal Recessive Polycystic Kidney Disease (ARPKD), is a rare, genetically inherited disorder caused by mutations in the PKHD1 gene. It manifests prenatally or in early infancy with bilateral, symmetrically enlarged kidneys due to fusiform dilatation of collecting ducts, accompanied by congenital hepatic fibrosis and variable pulmonary hypoplasia. Prognosis is highly heterogeneous: severe perinatal forms may present with Potter sequence and respiratory failure, while milder cases may survive into childhood or adulthood with progressive renal and hepatic complications. Management requires a multidisciplinary approach coordinated by pediatric nephrology, hepatology, pulmonology, nutrition, and genetics. Treatment is primarily supportive and organ-system–directed, as no disease-modifying pharmacotherapy is currently FDA- or EMA-approved for ARPKD.

Conservative management forms the cornerstone of care, especially in neonates and infants. Respiratory support is critical in the immediate postnatal period; up to 30% of severely affected neonates require mechanical ventilation due to pulmonary hypoplasia and impaired gas exchange. Continuous positive airway pressure (CPAP) or high-frequency oscillatory ventilation may be employed judiciously to avoid barotrauma. Fluid and electrolyte balance must be meticulously monitored: infants often exhibit polyuria secondary to impaired urinary concentrating ability, predisposing them to dehydration and hypernatremia. Oral or intravenous sodium supplementation may be necessary, particularly during intercurrent illness. Nutritional support is paramount—many infants suffer from failure to thrive due to increased metabolic demand, feeding intolerance, or gastroesophageal reflux. A high-calorie, low-sodium, age-appropriate formula—often supplemented with medium-chain triglyceride (MCT) oil for enhanced caloric density—is recommended. Gastrostomy tube placement may be indicated for persistent poor oral intake or aspiration risk. Regular surveillance includes serial renal ultrasound (to assess cyst burden, parenchymal echogenicity, and cortical thinning), Doppler assessment of renal artery flow, and measurement of glomerular filtration rate (GFR) via serum cystatin C–based equations (e.g., Schwartz-Lyon). Hepatic involvement necessitates periodic liver enzyme panels, abdominal ultrasound with elastography, and screening for portal hypertension (e.g., platelet count, splenomegaly, esophageal varices via endoscopy if clinically indicated).

Pharmacologic interventions remain largely symptomatic. Antihypertensive therapy is initiated promptly upon diagnosis of hypertension—present in >60% of older infants and children—with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) preferred due to their renoprotective effects and antiproteinuric properties. Diuretics (e.g., furosemide) are used cautiously to manage volume overload but avoided in dehydrated states. Growth hormone therapy may be considered in children with documented growth failure refractory to nutritional optimization, though evidence specific to ARPKD remains limited. Antibiotic prophylaxis is not routinely recommended, but prompt treatment of urinary tract infections (UTIs) is essential given the risk of pyelonephritis-induced renal scarring. Chronic kidney disease (CKD)-related complications—including anemia (managed with erythropoiesis-stimulating agents and iron supplementation), metabolic acidosis (corrected with oral sodium bicarbonate), and mineral bone disorder (treated with phosphate binders and active vitamin D analogs)—are addressed per KDIGO guidelines.

Surgical intervention is reserved for specific complications. Nephrectomy is rarely performed except in cases of massive, symptomatic renal enlargement causing respiratory compromise, intractable pain, recurrent infection, or severe hypertension unresponsive to medical therapy. Laparoscopic or robotic-assisted partial nephrectomy may be considered in select older children to preserve residual function, though data on long-term benefit are sparse. Portosystemic shunting (e.g., mesocaval shunt) or transjugular intrahepatic portosystemic shunt (TIPS) may be palliative for life-threatening variceal bleeding, though surgical shunts carry higher morbidity in young children. Liver transplantation is indicated for decompensated cirrhosis, recurrent variceal hemorrhage, or intractable ascites; combined liver-kidney transplantation is increasingly performed in patients with end-stage renal disease (ESRD) and advanced hepatic fibrosis, offering superior long-term survival compared to isolated kidney transplant due to reduced risk of native kidney recurrence and perioperative complications. Dialysis—peritoneal dialysis (PD) is first-line in infants due to hemodynamic stability and technical feasibility—bridges patients to transplantation. Hemodialysis is typically deferred until age 2–3 years unless PD fails.

China offers distinct advantages in the comprehensive management of ARPKD. First, the national newborn screening program—though not yet including ARPKD universally—has expanded prenatal ultrasound access, enabling earlier detection and referral to tertiary centers such as Peking University First Hospital and Shanghai Children’s Medical Center, both designated National Clinical Research Centers for Pediatric Nephrology. Second, China’s robust organ transplantation infrastructure, supported by the China Organ Transplant Response System (COTRS), has significantly shortened wait times for pediatric liver and kidney grafts; median wait time for pediatric liver transplant is now <6 months versus >12 months in many Western countries. Third, integrated traditional Chinese medicine (TCM) adjuncts—such as modified Liuwei Dihuang Wan or Huangqi decoctions—are rigorously studied in randomized controlled trials at institutions like Guangzhou University of Chinese Medicine and demonstrate potential benefits in reducing proteinuria and slowing eGFR decline, though mechanistic validation is ongoing. Fourth, telemedicine-enabled longitudinal follow-up through platforms like WeDoctor facilitates seamless coordination between provincial hospitals and national centers, improving adherence to surveillance protocols and early complication detection.

Recovery and long-term prognosis hinge on proactive, family-centered education and lifestyle adaptation. Parents should receive structured counseling on recognizing signs of dehydration (e.g., decreased wet diapers, sunken fontanelle), UTI (fever, irritability, foul-smelling urine), or variceal bleed (hematemesis, melena). Vaccination schedules must be strictly adhered to, with emphasis on pneumococcal, hepatitis B, and annual influenza vaccines; live vaccines are contraindicated in immunosuppressed transplant recipients. School reintegration planning should include individualized health plans addressing fatigue, medication timing, and bathroom access. Psychological support—via child life specialists and clinical psychologists—is integral, as children with ARPKD face elevated risks of anxiety, depression, and social isolation. Finally, genetic counseling is mandatory: recurrence risk is 25% for future pregnancies, and prenatal testing (chorionic villus sampling or amniocentesis with PKHD1 sequencing) or preimplantation genetic diagnosis (PGD) should be offered. With optimized conservative care, timely transplantation, and integrated psychosocial support, over 85% of children with non-lethal neonatal ARPKD now survive beyond age 5, and many achieve near-normal quality of life into adulthood.